ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Venomous Agent X (VX) and related organophosphonate nerve agents do their deadly work by deactivating the enzyme acetylcholinesterase. This causes the neurotransmitter acetylcholine to build up, poisoning the central and peripheral nervous systems. Doctors currently treat exposure to these nerve agents by managing the symptoms of acetylcholine accumulation. But there is a window of several hours between exposure to VX and the time its toxic effects take hold in which a therapy might be used to detoxify the organophosphate before it reaches its target. Working toward that goal, a team led by Stefan Kubik of the Kaiserslautern University of Technology developed sulfonatocalix[4]arenes substituted with a hydroxamic acid group (shown) that can deactivate VX and related compounds in three to five minutes under mild conditions (Angew. Chem, Int. Ed. 2016, DOI: 10.1002/anie.201606881). The positively charged organophosphonate slips into the negatively charged calixarene, where it is deactivated via reaction with the hydroxamic acid. The reaction is stoichiometric, which makes it less attractive than catalytic biological scavengers currently under development. But Kubik believes the calixarenes are a promising lead toward synthetic compounds that can scavenge VX and similar nerve agents.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X